Time and again, children resemble their parents

Journal of Nuclear Medicine

Volumn 49, Issue 10, 2008, Pages 1577-1578

  Hicks, Rodney J ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; RADIOPHARMACEUTICAL AGENT; TITANIUM 201; UNCLASSIFIED DRUG;

BEHAVIOR; BIOCHEMISTRY; CHOLECYSTITIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; GALLBLADDER CARCINOMA; GENETICS; GENOMICS; HEAD AND NECK CANCER; LUNG NON SMALL CELL CANCER; NUCLEAR MEDICINE; PATERNITY TEST; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SHORT SURVEY;

DIAGNOSTIC IMAGING; FLUORODEOXYGLUCOSE F18; HUMANS; INFLAMMATION; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 53749102375     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.052142     Document Type: Short Survey

References (19)

1. 18F-FDG PET for staging in patients with lung cancer. J Nucl Med. 2008;49:1606-1612.
2. 201Tl as a tumour-localizing agent: current status and future considerations. Nucl Med Commun. 1993;14:96-103.
3. 201T1-chloride uptake ratios in differentiating benign from malignant lesions: recommendations for ratio calculations and interpretation. Nucl Med Commun. 1995;16:145-149.
4. 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med. 2002;43:871-875.
5. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med. 1996;23:1409-1415.
6. Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972-1980.
7. Brown RS, Leung JY, Fisher SJ, et al. Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important? J Nucl Med. 1995;36:1854-1861.
8. Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med. 1995;36:1301-1306.
9. 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42:1412-1417.
10. 18F-FDG PET imaging and partial volume correction in the assessment of solitary pulmonary nodules. Eur J Nucl Med Mol Imaging. 2008;35:246-252.
11. Hustinx R, Smith RJ, Benard F, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med. 1999;26:1345-1348.
12. 18F-FDG PET. J Nucl Med. 2005;46:1819-1824.
13. 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med. 2006;47:1440-1446.
14. Yen TC, Ng KK, Ma SY, et al. Value of dual-phase 2-fluoro-2-deoxy-d- glucose positron emission tomography in cervical cancer. J Clin Oncol. 2003;21:3651-3658.
15. Koike I, Ohmura M, Hata M, et al. FDG-PET scanning after radiation can predict tumor regrowth three months later. Int J Radiat Oncol Biol Phys. 2003;57:1231-1238.
16. Hicks RJ, Mac Manus MP, Matthews JP, et al. Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Int J Radiat Oncol Biol Phys. 2004;60:412-418.
17. 18F-FDG PET for the lymph node staging of non-small cell lung cancer in a tuberculosis-endemic country: is dual time point imaging worth the effort? Eur J Nucl Med Mol Imaging. 2008;35:1305-1315.
18. 18F-FDG PET for the evaluation of gallbladder carcinoma. J Nucl Med. 2006;47:633-638.
19. Wang G, Lau EW, Shakher R, et al. How do oncologists deal with incidental abnormalities on whole-body fluorine-18 fluorodeoxyglucose PET/CT? Cancer. 2007;109:117-124.